Potent FFA1 (GPR40) agonist (EC50
= 3.6 nM in an IP3
assay in GPR40 transfected A9 cells). Inhibits insulin secretion from isolated pancreatic islets. Reduces blood glucose levels following oral glucose challenge in mice. Orally bioavailable.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Optimization of GPR40 agonists for type 2 diabetes.
Liu et al.
ACS Med.Chem.Lett., 2014;5:517